Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend up since Oct 14 · below the Ichimoku cloud · RSI 53 · MACD above its signal · 5% below its 52-week high
None of the 29 investors followed here reported a position in JDOC in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a JDOC trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1.1 | 1.2 | -6.1 | -0.0 | 2.0 | 6.3 | 0.7 | 3.2 | -3.3 | 1.3 | +6.0% | ||
| 2025 | 7.7 | 0.4 | -2.6 | -2.7 | -4.6 | 2.1 | -2.9 | 5.0 | 1.8 | 4.6 | 8.2 | -2.4 | +14.4% |
| 2024 | 2.2 | 3.6 | 2.7 | -3.8 | 1.8 | 2.2 | 2.7 | 5.5 | -4.3 | -4.6 | -0.9 | -12.0 | −6.1% |
| 2023 | 5.7 | +5.7% |
The fund will invest primarily in equity securities issued by pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology and life sciences companies which the adviser believes are leaders and where the magnitude and/or duration of future growth for these companies is underappreciated by the market. Under normal circumstances, the fund invests at least 80% of its assets in the equity securities of healthcare companies.
No recent headlines.